Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beard Energy Transition Acquisition Corp.BRD · Entity 129622 | Director | November 23, 2021 | November 23, 2021 |
| Comera Life Sciences Holdings, Inc.CMRA · Entity 94670 | 10% owner | December 27, 2023 | January 03, 2024 |
| Ernexa Therapeutics Inc.ERNA · Entity 8278 | 10% owner | February 10, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beard Energy Transition Acquisition Corp.
Report date November 23, 2021 · Filed November 23, 2021
This filing explicitly reported no securities owned.
Comera Life Sciences Holdings, Inc.
Report date December 27, 2023 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 12.0% Senior Secured Convertible NotesSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2024-12-29 | Direct | Not disclosed |
Reported balance
After 2023-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-29 · Purchase · Acquired Not disclosed · Balance Not disclosed F1: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2028-12-29 | Direct | 20,650,908 |
Reported balance
After 2023-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-29 · Purchase · Acquired 20,650,908 · Balance 20,650,908 F1: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. |
| Series A Convertible Perpetual Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.56 | IndirectBy LLC | 3,895.53 |
Reported balance
After 2023-12-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-27 · Purchase · Acquired 3,895.53 · Balance 3,895.53 F2: The preferred stock was acquired by Comera SPV LLC ("SPV") in a private transaction pursuant to a purchase agreement, dated as of December 27, 2023, with an unaffiliated, institutional investor. F3: The preferred stock is perpetual and therefore has no expiration date. F4: The reporting person is the General Partner of SPV. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof.
F2: The preferred stock was acquired by Comera SPV LLC ("SPV") in a private transaction pursuant to a purchase agreement, dated as of December 27, 2023, with an unaffiliated, institutional investor.
F3: The preferred stock is perpetual and therefore has no expiration date.
F4: The reporting person is the General Partner of SPV. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Ernexa Therapeutics Inc.
Report date February 10, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,779,440 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Purchase · Acquired 4,000,000 · Balance 6,779,440 F1: These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026. F2: The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.68 | Direct | 4,000,000 |
Reported balance
After 2026-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-10 · Purchase · Acquired 4,000,000 · Balance 4,000,000 F1: These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026. F2: The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. F3: The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026.
F2: The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50.
F3: The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 18, 2026 02:14 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants to Purchase Common Stock · Derivative | 4,000,000 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001104659-26-016680 · tm265959-2_4seq1.xml · derivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000,000 Underlying: Common Stock · 4,000,000 shares Expires not disclosed F1 · kind: These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026. F2 · price: The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. F3 · derivative.expiration_date: The warrants will expire on the earlier of (i) February 10, 2031 or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. Read SEC document |
| February 10, 2026 Filed Feb 18, 2026 02:14 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 4,000,000 | $0.50 | $2,000,000.00 |
DisclosureSEC source: 0001104659-26-016680 · tm265959-2_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,779,440 F1 · kind: These shares and warrants were purchased by the reporting person in the Issuer's follow-on offering pursuant to a prospectus supplement dated February 6, 2026, which closed on February 10, 2026. F2 · price: The combined purchase price in the Offering per share of Common Stock and accompanying warrant was $0.50. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:34 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 21,241,163 | $0.10 | $2,221,825.65 |
DisclosureSEC source: 0001104659-25-058644 · tm2517798-2_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,659,743 F1 · shares: On June 9, 2025, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the reporting person acquired 21,241,163 shares of the Issuer's Common Stock. F2 · balance_after: On June 2, 2025, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of Common Stock. As a result, the Reporting Person received 16,978 shares of the Issuer's Common Stock. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 14:54 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 3,768,397 | $0.10 | $394,174.33 |
DisclosureSEC source: 0001104659-25-032060 · tm2511399-2_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,401,602 F1 · shares: On April 2, 2025, pursuant to a private placement offering by the Issuer, the reporting person acquired 3,768,397 shares of the Issuer's Common Stock. F2 · balance_after: On December 3, 2024, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of common stock. As a result, the Reporting Person received 5,082 shares of the Issuer's common stock. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 3,125,976 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 17 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125,976 shares Expires 2028-12-15 F1 · derivative.exercise_price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · derivative.exercise_price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · date: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 2,475,524 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 16 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,475,524 shares Expires 2028-07-14 F1 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · date: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 523,512 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 15 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 523,512 shares Expires 2028-06-02 F1 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · date: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Sale6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | Not disclosed Strike: $2.86 | $3,540,000.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 14 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,237,762 shares Expires 2028-07-14 F1 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · date: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Sale12.0% Senior Convertible Notes due December 12, 2028 · Derivative | Not disclosed | Not disclosed Strike: $1.92 | $3,000,000.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 13 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125,976 shares Expires 2028-12-15 F1 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · date: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Conversion12.0% Senior Convertible Notes due September 24, 2025 · Derivative | Not disclosed | $0.00 Strike: $0.50 | $1,368,626.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 12 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,737,252 shares Expires 2025-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The Notes are automatically converted into shares of Common Stock upon the obtaining of Stockholder Approval (as defined in the Notes) and cannot be converted into Common Stock prior to obtaining Stockholder Approval. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | ConversionCommon Stock | 2,819,546 | $0.50 | $1,409,773.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,628,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · shares: Shares issued as a result the conversion of the Issuer's 12.0% Senior Convertible Notes due September 24, 2025 (the "September Notes") consisting of (i) 2,737,252 shares of Common Stock issued upon conversion of the principal amount of the September Notes and (ii) 82,294 shares issued upon conversion of the interest accrued on the September Notes. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 1,562,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 5 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,808,577 F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F7 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of December 15, 2028. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 5,420,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 4 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,245,589 F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F6 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 12.0% Senior Convertible Notes due December 12, 2028 in the aggregate principal amount of $3,000,000 plus applicable interest. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 1,237,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 3 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,824,766 F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F5 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of July 14, 2028. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 4,768,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587,004 F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F4 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 6.0% Senior Convertible Promissory Notes due 2028 in the aggregate principal amount of $3,300,000 plus applicable interest. Read SEC document |
| October 29, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 261,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,221 F1 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to (i) exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number), and F2 · price: (ii) exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collective, the "Exchange Transactions"). Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval (as defined in the Exchange Agreement), which occurred on October 29, 2024. F3 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of June 2, 2028. Read SEC document |
| September 24, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase12.0% Senior Convertible Notes due September 24, 2025 · Derivative | Not disclosed | $1,368,626.00 Strike: $0.50 | $1,368,626.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 11 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 2,737,252 shares Expires 2025-09-24 F11 · derivative.exercise_price: The reporting person entered into a Note Purchase Agreement with the Issuer on September 24, 2024, pursuant to which the reporting person acquired $1,368,626 principal amount of September Notes. F12 · derivative.exercise_date: The Notes are automatically converted into shares of Common Stock upon the obtaining of Stockholder Approval (as defined in the Notes) and cannot be converted into Common Stock prior to obtaining Stockholder Approval. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 3,125,976 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · derivative · entry 10 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125,976 shares Expires 2028-12-15 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · date: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 2,475,524 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · derivative · entry 9 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,475,524 shares Expires 2028-07-14 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · date: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | SaleWarrants (right to buy) · Derivative | 523,512 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · derivative · entry 8 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 523,512 shares Expires 2028-06-02 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · date: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · date: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Sale6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | Not disclosed Strike: $2.86 | $3,540,000.00 |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · derivative · entry 7 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,237,762 shares Expires 2028-07-14 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F4 · date: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · date: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F4 · price: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Sale12.0% Senior Convertible Notes due December 12, 2028 · Derivative | Not disclosed | Not disclosed Strike: $1.92 | $3,000,000.00 |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · derivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125,976 shares Expires 2028-12-15 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F4 · date: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · date: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F4 · price: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 1,562,988 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · nonDerivative · entry 5 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,808,577 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F10 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of December 15, 2028. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 5,420,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · nonDerivative · entry 4 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,245,589 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F4 · price: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F9 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 12.0% Senior Convertible Notes due December 12, 2028 in the aggregate principal amount of $3,000,000 plus applicable interest. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 1,237,762 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · nonDerivative · entry 3 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,824,766 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F8 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of July 14, 2028. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 4,768,783 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · nonDerivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,587,004 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F4 · price: The Reporting Person also agreed pursuant to the Exchange Agreement to exchange all their convertible notes for shares of Common Stock at an exchange ratio equal to (A) the sum expressed in U.S. dollars of (1) the principal amount of the applicable convertible note, plus (2) all accrued and unpaid interest thereon through the date the applicable convertible note is exchanged plus (3) all interest that would have accrued through, but not including, the maturity date of applicable convertible note if it was outstanding from the date such convertible note is exchanged through its maturity date, divided by (B) $1.00 (rounded up to the nearest whole number) (collectively with the Warrant Exchange, the "Exchange Transactions"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F7 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's 6.0% Senior Convertible Promissory Notes due 2028 in the aggregate principal amount of $3,300,000 plus applicable interest. Read SEC document |
| September 24, 2024 Filed May 7, 2025 15:48 UTC Amendment | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 261,756 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-045416 · tm2514116-1_4aseq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,221 F1 · date: On November 5, 2024, the Reporting Person filed a Form 4 that included an incorrect transaction date of October 29, 2024 for the Exchange Transactions (as defined below) based on the fact that under the Exchange Agreement (as defined below) consummation of the Exchange Transactions was conditioned upon Stockholder Approval (as defined in the Exchange Agreement). This amendment is being filed to reflect the correct transaction date for the Exchange Transactions of September 24, 2024 based on the analysis set forth in footnote 2 below. F2 · date: Upon review of the relevant facts and caselaw, the Reporting Person has determined that the Stockholder Approval was not a material condition for the Exchange Transactions as the Reporting Person and several other stockholders exchanging securities with the Company had entered into support agreements with the Issuer on September 24, 2024 (as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 25, 2024) pursuant to which each stockholder agreed to vote all of their eligible voting securities in favor of the Stockholder Approval. According to the Issuer's Definitive Proxy Statement filed with the SEC on October 7, 2024, the parties to the support agreements owned approximately 48% of the Issuer's outstanding Common Stock, which meant that the satisfaction of the condition was practically assured and the Reporting Person became irrevocably committed to the Exchange Transactions on September 24, 2024 after all parties entered into the support agreements. F3 · price: The reporting person entered into an Exchange Agreement with the Issuer on September 24, 2024 (the "Exchange Agreement"), pursuant to which the reporting person agreed to exchange all their warrants to purchase shares of the Issuer's common stock, par value $0.005 per share ("Common Stock") at an exchange ratio of 0.5 of a share of Common Stock for every one share of Common Stock issuable upon exercise of the applicable warrant (rounded up to the nearest whole number) (the "Warrant Exchange"). F5 · price: Consummation of the Exchange Transactions was conditioned upon the Issuer obtaining Stockholder Approval, which occurred on October 29, 2024. F6 · price: Shares issued pursuant to the Exchange Agreement in exchange for all of the reporting person's warrants to purchase shares of Common Stock at an exercise price of $1.43 per share with an expiration date of June 2, 2028. Read SEC document |
| September 23, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 83,916 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 10 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,475,524 Underlying: Common Stock · 83,916 shares Expires 2028-07-14 F10 · date: On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. F10 · price: On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. Read SEC document |
| September 23, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | Not disclosed Strike: $2.86 | $120,000.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 9 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 41,958 shares Expires 2028-07-14 F10 · date: On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. F10 · price: On September 23, 2024, the reporting person agreed to forgive a personal loan for $50,000 to a second investor (separate from the investor referenced in footnote 9) in the Issuer's July 2023 private placement in exchange for all of such invetsor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. Read SEC document |
| September 23, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 83,916 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 8 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,391,608 Underlying: Common Stock · 83,916 shares Expires 2028-07-14 F9 · date: On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. F9 · price: On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. Read SEC document |
| September 23, 2024 Filed Nov 5, 2024 17:42 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | Not disclosed Strike: $2.86 | $120,000.00 |
DisclosureSEC source: 0001104659-24-114222 · tm2427444-1_4seq1.xml · derivative · entry 7 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 41,958 shares Expires 2028-07-14 F9 · date: On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. F9 · price: On September 23, 2024, the reporting person agreed to forgive a personal loan to an investor in the Issuer's July 2023 private placement for $50,000 in exchange for all of such investor's warrants to purchase shares of Common Stock and 6.0% Senior Convertible Promissory Notes due 2028. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 20:38 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 20,650,908 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001104659-24-001041 · tm241917-1_4seq1.xml · derivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,650,908 Underlying: Common Stock · 20,650,908 shares Expires 2028-12-29 F1 · kind: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 20:38 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | Purchase12.0% Senior Secured Convertible Notes · Derivative | Not disclosed | $567,900.00 Strike: $0.06 | $567,900.00 |
DisclosureSEC source: 0001104659-24-001041 · tm241917-1_4seq1.xml · derivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 10,325,454 shares Expires 2024-12-29 F1 · kind: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 29, 2023, pursuant to which the reporting person acquired (i) $567,900 principal amount of the Issuer's 12.0% Senior Secured Convertible Notes (the "Notes") and (ii) 20,650,908 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $0.055 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. Read SEC document |
| December 27, 2023 Filed Jan 3, 2024 20:38 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseSeries A Convertible Perpetual Preferred Stock · Derivative | 3,895.53 | $500,000.00 Strike: $12.56 | $1,947,765,000.00 |
DisclosureSEC source: 0001104659-24-001041 · tm241917-1_4seq1.xml · derivative · entry 3 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 3,895.53 Underlying: Common Stock · 310,153 shares Expires not disclosed F2 · kind: The preferred stock was acquired by Comera SPV LLC ("SPV") in a private transaction pursuant to a purchase agreement, dated as of December 27, 2023, with an unaffiliated, institutional investor. F3 · derivative.expiration_date: The preferred stock is perpetual and therefore has no expiration date. F4 · ownership.nature: The reporting person is the General Partner of SPV. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 523,512 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 523,512 Underlying: Common Stock · 523,512 shares Expires 2028-06-02 F5 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | OtherWarrants (right to buy) · Derivative | 523,512 | Not disclosed Strike: $3.28 | Not disclosed |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 5 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 523,512 shares Expires 2028-06-02 F5 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on December 2, 2022 to reduce the exercise price from $3.28 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 2,307,692 | Not disclosed Strike: $1.43 | Not disclosed |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 4 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,307,692 Underlying: Common Stock · 2,307,692 shares Expires 2028-07-14 F4 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | OtherWarrants (right to buy) · Derivative | 2,307,692 | Not disclosed Strike: $2.61 | Not disclosed |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 3 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,307,692 shares Expires 2028-07-14 F4 · price: The transactions reported in Table II above involved the amendment of an outstanding warrant issued on July 14, 2023 to reduce the exercise price from $2.61 per share to $1.43 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new one. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 3,125,976 | $0.13 Strike: $1.43 | $390,747.00 |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,125,976 Underlying: Common Stock · 3,125,976 shares Expires 2028-12-15 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F3 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation. Read SEC document |
| December 14, 2023 Filed Dec 20, 2023 15:05 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase12.0% Senior Convertible Notes · Derivative | Not disclosed | $3,000,000.00 Strike: $1.92 | $3,000,000.00 |
DisclosureSEC source: 0001104659-23-127551 · tm2333295-1_4seq1.xml · derivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 1,562,988 shares Expires 2028-12-15 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on December 14, 2023, pursuant to which, on December 15, 2023, the reporting person acquired (i) $3,000,000 principal amount of the Issuer's 12.0% Senior Convertible Notes (the "Notes") and (ii) 3,125,976 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $1.43 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F2 · derivative.underlying_shares: The conversion of the Notes is subject to a 19.99% beneficial ownership limitation. Read SEC document |
| September 11, 2023 Filed Sep 11, 2023 20:24 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 5,134,474 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001104659-23-099800 · tm2325724-1_4seq1.xml · derivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,134,474 Underlying: Common Stock · 5,134,474 shares Expires 2028-09-11 F1 · kind: On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. F1 · price: On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. Read SEC document |
| September 11, 2023 Filed Sep 11, 2023 20:24 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseCommon Stock | 2,053,789 | $0.51 | $1,049,896.94 |
DisclosureSEC source: 0001104659-23-099800 · tm2325724-1_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,813,650 F1 · kind: On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. F1 · price: On September 11, 2023, pursuant to a private placement offering by the Issuer and following the receipt of stockholder approval, the Reporting Person acquired 2,053,789 shares of the Issuer's Common Stock and Warrants to purchase up to 5,134,474 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. Read SEC document |
| July 31, 2023 Filed Aug 25, 2023 19:33 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 2,200,488 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001104659-23-095433 · tm2323568-1_4seq1.xml · derivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200,488 Underlying: Common Stock · 2,200,488 shares Expires 2028-07-31 F1 · kind: On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. F6 · shares: The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation. F1 · price: On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. Read SEC document |
| July 31, 2023 Filed Aug 25, 2023 19:33 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseCommon Stock | 880,195 | $0.51 | $450,043.70 |
DisclosureSEC source: 0001104659-23-095433 · tm2323568-1_4seq1.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,759,861 F1 · kind: On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. F1 · price: On July 31, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 880,195 shares of the Issuer's Common Stock and Warrants to purchase up to 2,200,488 shares of Common Stock. The combined purchase price per share of Common Stock and accompanying Warrant in the offering was $0.51125, with all of the purchase price allocated to the shares of Common Stock. Read SEC document |
| July 13, 2023 Filed Aug 25, 2023 23:34 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 2,307,692 | $0.13 Strike: $2.61 | $288,461.50 |
DisclosureSEC source: 0001104659-23-095434 · tm2323568-3_4seq1.xml · derivative · entry 2 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,307,692 Underlying: Common Stock · 2,307,692 shares Expires 2028-07-14 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F3 · derivative.underlying_shares: The exercisability of the Warrants is subject to a 19.99% beneficial ownership limitation. Read SEC document |
| July 13, 2023 Filed Aug 25, 2023 23:34 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | $3,300,000.00 Strike: $2.86 | $3,300,000.00 |
DisclosureSEC source: 0001104659-23-095434 · tm2323568-3_4seq1.xml · derivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 1,153,846 shares Expires 2028-07-14 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired (i) $3,300,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 2,307,692 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant) in accordance with Nasdaq rules. F2 · derivative.underlying_shares: The conversion of the Notes is subject to a 19.99% beneficial ownership limitation. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 16:45 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseWarrants to Purchase Common Stock · Derivative | 743,243 | $0.25 Strike: $1.23 | $185,810.75 |
DisclosureSEC source: 0000899243-23-001182 · doc4.xml · derivative · entry 6 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 743,243 Underlying: Common Stock · 1,486,486 shares Expires 2028-01-04 F1 · kind: On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant. F1 · price: On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 16:45 UTC | Comera Life Sciences Holdings, Inc. CMRA · Entity 94670 | PurchaseCommon Stock | 743,243 | $1.23 | $914,188.89 |
DisclosureSEC source: 0000899243-23-001182 · doc4.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,879,666 F1 · kind: On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant. F1 · price: On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:02 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 523,512 | $0.13 Strike: $3.28 | $65,439.00 |
DisclosureSEC source: 0001140361-22-044639 · form4.xml · derivative · entry 2 Cherington Charles · CIK 0001448698 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,512 Underlying: Common Stock, par value $0.005 per share · 523,512 shares Expires 2028-06-02 F1 · derivative.exercise_price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules. F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:02 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseCommon Stock | 261,756 | $3.28 | $858,559.68 |
DisclosureSEC source: 0001140361-22-044639 · form4.xml · nonDerivative · entry 1 Cherington Charles · CIK 0001448698 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,465 F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on November 23, 2022, pursuant to which, on December 2, 2022, the reporting person acquired an aggregate of 261,756 units for a purchase price of $3.53 per unit, each unit consisting of one share of common stock, par value $0.05 per share ("Common Stock"), and two warrants, each exercisable to purchase one share of Common Stock at an exercise price of $3.28 per share. The purchase price for each unit included $0.125 for each warrant in accordance with Nasdaq rules. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.